Alto Neuroscience, Inc. (ANRO)
(Real Time Quote from BATS)
$11.16 USD
+0.16 (1.46%)
Updated Oct 21, 2025 02:04 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANRO 11.16 +0.16(1.46%)
Will ANRO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ANRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANRO
All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy
ANRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ANRO
Analysts’ Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Glaukos (GKOS)
Expansion Breakout appears for ANRO after 80.92% move
Alto Neuroscience price target raised to $16 from $10 at Baird
Alto Neuroscience price target raised by $6 at Baird, here's why
Midday Fly By: AWS hit by outage, Kering sells beauty unit